KR101452518B1 - Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 - Google Patents

Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 Download PDF

Info

Publication number
KR101452518B1
KR101452518B1 KR1020087006891A KR20087006891A KR101452518B1 KR 101452518 B1 KR101452518 B1 KR 101452518B1 KR 1020087006891 A KR1020087006891 A KR 1020087006891A KR 20087006891 A KR20087006891 A KR 20087006891A KR 101452518 B1 KR101452518 B1 KR 101452518B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
present
glucose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020087006891A
Other languages
English (en)
Korean (ko)
Other versions
KR20080059164A (ko
Inventor
앤드류 레우메
마이클 에스. 사포리토
Original Assignee
멜리어 파마슈티칼스 아이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 멜리어 파마슈티칼스 아이, 인코포레이티드 filed Critical 멜리어 파마슈티칼스 아이, 인코포레이티드
Publication of KR20080059164A publication Critical patent/KR20080059164A/ko
Application granted granted Critical
Publication of KR101452518B1 publication Critical patent/KR101452518B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
KR1020087006891A 2005-08-22 2006-08-22 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 Expired - Lifetime KR101452518B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70979805P 2005-08-22 2005-08-22
US60/709,798 2005-08-22
US80853306P 2006-05-26 2006-05-26
US60/808,533 2006-05-26
PCT/US2006/032788 WO2007024863A2 (en) 2005-08-22 2006-08-22 Methods and formulations for modulating lyn kinase activity and treating related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016962A Division KR101577554B1 (ko) 2005-08-22 2006-08-22 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제

Publications (2)

Publication Number Publication Date
KR20080059164A KR20080059164A (ko) 2008-06-26
KR101452518B1 true KR101452518B1 (ko) 2014-10-21

Family

ID=37635750

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087006891A Expired - Lifetime KR101452518B1 (ko) 2005-08-22 2006-08-22 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
KR1020147016962A Expired - Lifetime KR101577554B1 (ko) 2005-08-22 2006-08-22 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147016962A Expired - Lifetime KR101577554B1 (ko) 2005-08-22 2006-08-22 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제

Country Status (11)

Country Link
US (8) US7776870B2 (enExample)
EP (1) EP1924262B1 (enExample)
JP (1) JP5113752B2 (enExample)
KR (2) KR101452518B1 (enExample)
AT (1) ATE533488T1 (enExample)
AU (1) AU2006283211B2 (enExample)
BR (1) BRPI0615046C1 (enExample)
CA (1) CA2620065C (enExample)
IL (1) IL189603A0 (enExample)
NZ (1) NZ565955A (enExample)
WO (1) WO2007024863A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
EP2120581A4 (en) * 2007-02-20 2011-03-16 Melior Pharmaceuticals I Inc METHODS OF IDENTIFYING LYN KINASE ACTIVATORS
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis
EP2180894A4 (en) * 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2011150300A1 (en) * 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
SG11201403207WA (en) * 2011-12-12 2014-09-26 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes
WO2014100636A2 (en) * 2012-12-20 2014-06-26 The Trustees Of Columbia University In The City Of New York Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator
JO3546B1 (ar) 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
CA3088178A1 (en) 2018-02-21 2019-08-29 Melior Pharmaceuticals I, Inc. Treatment of liver diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
BE790125A (fr) * 1971-10-29 1973-04-16 Pfizer Nouvelles pyrimidinones et nouvelles hydroxypyrimidines
US4080454A (en) 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9214720D0 (en) 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
US20050208054A1 (en) 2003-12-09 2005-09-22 University Of Massachusetts Methods of identifying insulin response modulators and uses therefor
EP1541694A1 (en) 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
WO2007016975A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
US20070025953A1 (en) 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
SI1924264T1 (sl) 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
KR100881728B1 (ko) 2007-05-04 2009-02-06 주식회사 하이닉스반도체 루테늄전극을 구비한 반도체소자 및 그 제조 방법
EP2180894A4 (en) 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP3110946B1 (en) 2014-02-24 2021-09-01 Energesis Pharmaceuticals Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
EP3609500B1 (en) * 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines

Also Published As

Publication number Publication date
CA2620065C (en) 2011-03-29
US11033548B2 (en) 2021-06-15
AU2006283211A1 (en) 2007-03-01
JP2009506043A (ja) 2009-02-12
KR20080059164A (ko) 2008-06-26
KR20140096141A (ko) 2014-08-04
US7776870B2 (en) 2010-08-17
US20160136165A1 (en) 2016-05-19
WO2007024863A2 (en) 2007-03-01
ATE533488T1 (de) 2011-12-15
KR101577554B1 (ko) 2015-12-14
JP5113752B2 (ja) 2013-01-09
US20070093516A1 (en) 2007-04-26
US20190321362A1 (en) 2019-10-24
US20180125845A1 (en) 2018-05-10
US9763945B2 (en) 2017-09-19
CA2620065A1 (en) 2007-03-01
US8343985B2 (en) 2013-01-01
US20140163054A1 (en) 2014-06-12
BRPI0615046B1 (pt) 2020-01-14
US9216959B2 (en) 2015-12-22
NZ565955A (en) 2011-08-26
US20100278804A1 (en) 2010-11-04
US12070461B2 (en) 2024-08-27
US20210361652A1 (en) 2021-11-25
BRPI0615046C1 (pt) 2021-05-25
IL189603A0 (en) 2008-08-07
US10251883B2 (en) 2019-04-09
EP1924262B1 (en) 2011-11-16
AU2006283211B2 (en) 2012-06-21
HK1120738A1 (en) 2009-04-09
BRPI0615046A2 (pt) 2011-04-26
US8835448B2 (en) 2014-09-16
US20130095182A1 (en) 2013-04-18
BRPI0615046B8 (pt) 2020-01-28
WO2007024863A3 (en) 2007-08-02
EP1924262A2 (en) 2008-05-28
WO2007024863A9 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
US12070461B2 (en) Methods and formulations for modulating Lyn kinase activity and treating related disorders
CN102834099B (zh) Dgat1抑制剂的用途
JP2010534668A (ja) Ｉｒｓ−１及びａｋｔを活性化する方法
JP2010518860A (ja) Ｌｙｎキナーゼの活性化剤の同定方法
WO2011150300A1 (en) Prevention of pancreatic beta cell degeneration
KR20080012896A (ko) 췌장염 예방 및 치료제
CN101287467B (zh) 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
AU2012227275B2 (en) Method and formulations for modulating Lyn kinase activity and treating related disorders
AU2014221302A1 (en) Method and formulations for modulating Lyn kinase activity and treating related disorders
HK1120738B (en) Methods and formulations for modulating lyn kinase activity and treating related disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20100112

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110822

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130420

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20131227

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131227

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20130420

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140620

PJ0201 Trial against decision of rejection

Patent event date: 20140620

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20140730

Appeal identifier: 2014101003799

Request date: 20140620

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140620

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140620

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140226

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20130820

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20110822

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20140801

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140722

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141013

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141013

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171019

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171019

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20181004

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181004

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20191021

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20191021

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20201021

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20201021

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20211020

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20211020

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20221005

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20221005

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240906

Start annual number: 11

End annual number: 11